DYNE THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENTLoan Agreement • July 23rd, 2020 • Dyne Therapeutics, Inc. • North Carolina
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of February 20, 2020, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and DYNE THERAPEUTICS, INC. (collectively with each of the other Persons, if any, that join as a co-Borrower hereunder are collectively referred to as the “Borrowers” and individually as a “Borrower”).
DYNE THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2018 STOCK INCENTIVE PLANRestricted Stock Agreement • July 23rd, 2020 • Dyne Therapeutics, Inc. • Delaware
This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 2018, between Dyne Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Recipient”).
SUBLEASE AGREEMENTSublease Agreement • July 23rd, 2020 • Dyne Therapeutics, Inc. • Massachusetts
This Sublease Agreement (the “Sublease”) is made as of May 20, 2019 (the “Effective Date”) by and between ARRAKIS THERAPEUTICS, INC., a Delaware corporation (“Sublandlord”) and DYNE THERAPEUTICS, INC., a Delaware corporation (“Subtenant”), in the following factual context:
November 29, 2018Offer Letter • July 23rd, 2020 • Dyne Therapeutics, Inc.
The Offer Letter dated March 21, 2018 (the “Offer Letter”) between you and Dyne Therapeutics, Inc. (the “Company”) provides that you will serve as the Chief Scientific Officer of the Company and that you will report to the Chief Executive Officer of the Company. In connection with your election to President and Chief Executive Officer of the Company on the date hereof, the Company and you agree as follows:
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENT By and...License Agreement • July 23rd, 2020 • Dyne Therapeutics, Inc. • New York
This agreement (this “Agreement”), dated the 27 day of April, 2020 (the “Effective Date”), is by and between Dyne Therapeutics Inc., a Delaware corporation with a place of business at 830 Winter Street, Waltham, MA 02451, USA (“Dyne”), and The University of Mons, a university with a place of business at Place du Parc 20, 7000 Mons, Belgium (“UMONS”).
